Wynn Hospital lifts restrictions for maternity, pediatric wards
UTICA, NY (WUTR/WFXV/WPNY) — The Wynn Hospital in Utica has lifted their visitor restrictions for the Maternal Child and Pediatric wards.
The hospital said in an announcement that the restrictions on visitors to those two wards were to better protect patients and employees from various illnesses, including the flu and RSV. The hospital has said the New York State Department of Health, as well as leaders from the Mohawk Valley Health System Maternity group, found these illnesses to no longer be prevalent.
Visitation regulations will now be as follows:
In the Labor and Delivery unit, two support persons, including a doula if requested, may accompany the patient throughout the delivery period until their discharge home. These persons must wear a green bracelet; there is no switching out of support persons.
The persons may be the patent's spouse, partner, sibling, parent or any other persons over the age of 16. Those two persons may be with the patient outside of regular visiting hours.
After delivery, two more persons may visit the patient until they are transferred to the hospital's Mother and Baby Unit. Only four total people are allowed in the room at one time.
In the Mother and Baby Unit, visiting hours will be from 8 am to 2 pm and 4 pm to 8 pm, with a designated quiet time from 2 pm to 4 pm. During these hours, the two support people from Labor and Delivery and another two visitors may be on the unit.
Siblings of the newborn will be allowed to visit with an adult visitor. However, they may not be left unattended with the mother. Only four total visitors will be allowed in the mother's room at one time.
In the Neonatal ICU, visiting hours will be from 8 am to 8 pm. All adult visitors must be accompanied by their primary caregiver and show proper ID.
Grandparents may visit without parents if they have been given written permission by the primary caregiver on the visitation form. Grandparents will not be allowed to bring any visitors with them.
A total of two adult visitors — one of those being the primary caregiver — will be allowed at the bedside of each newborn at any time. This is in addition to a minor sibling.
Siblings will be allowed to visit with an adult, but may not be left unattended with the caregiver. Only one parent will be able to stay overnight with the newborn.
Visitors to the Neonatal ICU may be asked about the presence of symptoms from flu, COVID or RSV.
In the Pediatric Unit, the patient shall designate two support persons over 16 years old at the time of admission. Those persons will be permitted to visit the patient with the parents present. Siblings of the patient are allowed to visit with an adult during normal visiting hours.
The hospital has advised that if visitors feel ill, they should stay home and delay their visit until they feel better.
For more information on visitation, you are encouraged to visit the MVHS website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
How AI could help stop the next pandemic before it starts
Could artificial intelligence tools be used to stop the next pandemic before it starts? During the Covid pandemic, new technology developed by researchers at Johns Hopkins and Duke universities didn't exist. But, for the first time, researchers there say they've devised a revolutionary large language modeling tool - the type of generative AI used in ChatGP - to help predict the spread of any infectious disease, such as bird flu, monkeypox, and RSV. That could help save lives and reduce infections. 'Covid-19 elucidated the challenge of predicting disease spread due to the interplay of complex factors that were constantly changing,' Johns Hopkins' Lauren Gardner, a modeling expert who created the Covid dashboard that was relied upon by people worldwide during the pandemic, said in a statement. 'When conditions were stable the models were fine. However, when new variants emerged or policies changed, we were terrible at predicting the outcomes because we didn't have the modeling capabilities to include critical types of information,' she added. 'The new tool fills this gap.' Gardner was one of the authors of the study published Thursday in the Nature Computational Science journal. The tool, named PandemicLLM, considers recent infection spikes, new variants, and stringent protective measures. The researchers utilized data that had never been used before in pandemic prediction tools, finding that PandemicLLM could accurately predict disease patterns and hospitalization trends one to three weeks out. The data included rates of cases hospitalizations and vaccines, types of government policies, characteristics of disease variants and their prevalence, and state-level demographics. The model incorporates these elements to predict how they will come together and affect how disease behaves. They retroactively applied PandemicLLM to the Covid pandemic, looking at each state over the course of 19 months. The authors said the tool was particularly successful when the outbreak was in flux. It also outperformed existing state-of-the-art forecasting methods, including the highest performing ones on the Centers for Disease Control and Prevention's CovidHub. 'Traditionally we use the past to predict the future,' author Hao 'Frank' Yang, a Johns Hopkins assistant professor of civil and systems engineering, said. 'But that doesn't give the model sufficient information to understand and predict what's happening. Instead, this framework uses new types of real-time information.' Going forward, they are looking at how large language models can replicate the ways individuals make decisions about their health. They hope that such a model would help officials to design safer and more effective policies. More than a million Americans have died from Covid. It's not a matter of if there will be a next pandemic, but when. Right now, the U.S. is dealing with the spread of H5N1 bird flu, RSV, HMPV, pertussis, and measles, among other health concerns. Vaccination rates for measles have plunged since the pandemic, and general vaccine hesitancy has increased. That has resulted in fears that the nation could see decades of health progress reversed. Furthermore, U.S. health officials have acted to separate from global efforts to respond to pandemics, withdrawing from the World Health Organization earlier this year. Last month, they limited access to Covid vaccines for certain groups. 'We know from Covid-19 that we need better tools so that we can inform more effective policies,' Gardner said. 'There will be another pandemic, and these types of frameworks will be crucial for supporting public health response.'
Yahoo
2 days ago
- Yahoo
Down 80%, Should You Buy the Dip on Moderna?
Moderna stock has dropped along with demand for a product that once drove tremendous growth: the coronavirus vaccine. Investors have remained focused on those declines -- and haven't yet recognized Moderna's long-term potential. 10 stocks we like better than Moderna › A few years ago, Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and saw its stock price skyrocket. The biotech went on to generate billions of dollars in revenue and profit amid soaring demand for its vaccine in those earlier days of the pandemic. But in later stages of the health crisis, fewer people rushed to get vaccinated, and this had a significant impact on Moderna's earnings -- and stock performance. Though Moderna has since won approval for updated versions of its vaccine and approval for another respiratory shot and the company has cut costs, the earnings and stock performance path remain difficult. But there are reasons to be optimistic about Moderna's long-term prospects as it has a robust late-stage pipeline ready to potentially deliver several products. Considering the full picture, down 80% over the past year, is Moderna a buy? Let's find out. So, as mentioned, Moderna was a brilliant success story just a few years ago. The company even proved the safety and efficacy of a new technology based on messenger RNA. This is important because it's a technology Moderna uses throughout its pipeline. The company's mRNA technique involves teaching the body to produce a particular protein that will protect it from or help it fight a virus or disease. Considering the depth of the pandemic, regulators helped speed coronavirus vaccines to the finish line, but it's worth keeping in mind that these products were based on years of research. Now, of course, investors have to be more patient and wait longer for Moderna's products to earn a regulatory nod because they aren't being approved for an early pandemic situation. As a result, Moderna right now continues to generate most of its revenue from the coronavirus vaccine, and it also brings in revenue from sales of its respiratory syncytial virus (RSV) vaccine, approved last year. Unfortunately for Moderna and its investors, however, coronavirus vaccine sales have declined, and the RSV vaccine hasn't performed as well as initially expected. But before throwing in the towel on Moderna, it's key to remember that better days are likely down the road. The company is at a point of transition right now as it prepares for what could be a great number of product launches ahead. In fact, Moderna recently reiterated it may roll out as many as 10 new products within the next few years. These products represent a total addressable market of $30 billion, so this could offer revenue a major boost. These programs also span many indications, from cytomegalovirus to oncology -- this is positive because Moderna won't depend on just one or two treatment areas in the future, reducing risk if one product sees a slowdown. It's also important to note that there's less risk of a slowdown when treating an ever-present virus or disease versus dealing with a pandemic situation -- pandemics result in steep gains, but when the situation improves, sales may sharply drop off. Meanwhile, Moderna has progressed nicely on its cost cutting program, and beyond this year, plans to reduce as much as $1.7 billion in estimated GAAP operating costs by 2027. Now let's return to our question: After Moderna's 80% drop, is the stock a buy? Moderna still faces challenges ahead. For example, the company recently lost U.S. government funding for its investigational bird flu vaccine, and uncertainty about the policies of President Trump's administration on vaccines could add to headwinds. On top of this, investors still often view Moderna as a COVID vaccine company and focus on declines in demand for that product. These elements could weigh on the stock's performance. But for investors who don't mind some volatility and plan on holding on to the stock for at least five years, Moderna makes an exciting biotech buy right now. If the company even partially reaches its product launch goal, the long-term revenue picture could look very bright. Before you buy stock in Moderna, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Moderna wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor's total average return is 987% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. Down 80%, Should You Buy the Dip on Moderna? was originally published by The Motley Fool
Yahoo
2 days ago
- Yahoo
COVID isn't over. RFK Jr.'s vaccine recommendation is a terrible choice.
The recent U.S. Department of Health and Human Services' announcement to no longer recommend the COVID-19 vaccine for pregnant women and children may be one of the worst public health decisions in the history of the United States, having a long-lasting detrimental impact on the future of our society, our children. The logic behind this decision is obscure at best, which may be why the Centers for Disease Control and Prevention referred questions regarding this policy to the U.S. Health Secretary, Robert F. Kennedy Jr., and to the U.S. Dept of Health and Human Services. For women and children, COVID-19 can be a serious disease, and COVID-19 vaccines and boosters help protect the pregnant mother, newborns and children. Pregnancy is a risk factor for severe COVID-19. The British Medical Journal published a large review of studies and concluded that COVID-19 increases the risk of maternal death and severe maternal morbidities (e.g., mechanical ventilation, thromboembolic disease). On one hand, the federal government recommends a COVID-19 booster for those over the age of 65 and for younger adults and children who have at least one risk factor, but then not recommend for those who are at risk because they are pregnant. COVID-19 vaccinations have been observed to effectively increase antibody levels against SARS-CoV-2 (the virus which causes COVID-19) and reduce the chances of a premature delivery. COVID-19 boosters are also safe during pregnancy and have not been found to be associated with spontaneous abortions. The decision to withhold COVID-19 vaccinations for children demonstrates a myopic approach to science and a lack of critical thinking. It appears policymakers are only focused on the prevention of death and hospitalization, defining this outcome as severe disease and assuming everything else is mild. This approach ignores the severe and chronic disabling effects of long COVID in children. It is true that on average children have milder COVID-19 infections and develop long COVID less commonly than adults. However, milder does not mean mild, and less common does not mean uncommon. It is estimated that approximately 4% of children will develop long COVID, compared to 10% to 26% for adults. This is way too high of an incidence for children, especially when re-infections are all too common. Long COVID in children can be serious. COVID-19 increases the chances of a child developing diabetes, other seemingly unrelated infections (for example respiratory syncytial virus [RSV] infections) and cognitive, mental health problems. Vaccinations have been found to reduce the chances of children developing long COVID. So maybe we should recommend and not discourage their use. Children can also spread the disease and place others at risk. This was known early on in the pandemic. I'm not sure how the public began to believe children did not pose a risk to others. Children are germ magnets, a life principle held by many parents and grandparents. Children readily spread every respiratory disease that I can think of. Why would COVID be any different? Opinion: Measles misinformation is hurting our kids while Trump government self-destructs How does our nation confront these public health risks? Simple, blame problems on lockdowns, ignore epidemiological evidence and quit counting cases. Then recommend against pregnant mothers and children receiving the vaccine. Clinical studies, medical record data and data from the V-Safe program have documented the vaccine's safety. VAERS (Vaccine Adverse Event Reporting System) is not intended or designed to determine the risks of complications, only to identify potential complications to be investigated. Similar to Facebook, inaccurate or malicious reports can also be entered by AI bots and foreign adversaries to stir social discontent. In general, vaccines are watered-down infections. They boost your immunity while markedly decreasing, but not completely eliminating, severe complications. The mRNA vaccine does not change one's DNA, and the dosage of the spike protein is much smaller than one receives from an infection. If vaccines are as dangerous as social media disinformation says, then multiply these dangers by several magnitudes when an infection develops. If one is worried about mRNA, then obtain the protein-based vaccine, Novavax, which may have lower side effects and should have better standardization of the delivery dosage. Opinion: We have money to fight Kentucky's opioid crisis. Let's not waste it. We soon will be at risk of facing another wave of COVID from the Nb.1.8.1 variant, which is currently spreading across Southeast Asia and just landed in the United States. This variant has increased infectivity and immune-evasive properties. Everyone should become vaccinated and up to date with their COVID-19 boosters, including pregnant women and children. COVID is not over, it is still dangerous, and can cause serious long-term sequelae that may not be evident for months or years after the acute infection. We need to update our nation's vaccination policy, not based on political populism, but to reflect the realities of the world we are living in. Agree or disagree? Submit a letter to the editor. Kevin Kavanagh is a retired physician from Somerset, Kentucky and chairman of Health Watch USA. This article originally appeared on Louisville Courier Journal: I'm a retired doctor. Kennedy's COVID policy will hurt US. | Opinion
